Catalog No.
PHC34601
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human CFH (Glu19-Pro346).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Complement factor H,CFH,H factor 1,HF1,HF,HF2
Concentration
0.52 mg/ml
Purification
Purified by antigen affinity column.
Accession
P08603
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Target complement factor H / serum amyloid a signaling in trichloroethylene-induced immune kidney injury., PMID:40373713
Long-Term Outcomes of Anticomplement Factor H Antibody Positive Versus Negative Atypical Hemolytic Uremic Syndrome., PMID:40352901
Long-term GABA supplementation mitigates anxiety by modulating complement and neuroinflammatory pathways., PMID:40274802
Clarifying criteria for complement-mediated TMA in patients without CFH antibodies or complement variants identified., PMID:40254367
Real-world use of complement inhibitors for haemolytic uraemic syndrome: an analysis of the European Rare Kidney Disease Registry cohort., PMID:40224677
The sialome of the retina, alteration in age-related macular degeneration (AMD) pathology and potential impacts on Complement Factor H., PMID:40161805
Glomerular mesangial cells derived complement factor H regulates complement activation, influences cell proliferation, and maintains actin cytoskeleton., PMID:40157080
Common Haplotypes within the Chromosome 1q31.3 Region Determine Systemic Concentrations of the Entire Complement Factor H Protein Family., PMID:40139172
A tumor-binding antibody with cross-reactivity to viral antigens., PMID:40009215
Atypical Hemolytic Uremic Syndrome Associated with BNT162b2 mRNA COVID-19 Vaccine in a Kidney Transplant Recipient: A Case Report and Literature Review., PMID:39997466
Human Factor H and anti-Neisserial surface protein A (NspA) antibodies compete for overlapping binding sites on meningococcal NspA., PMID:39992115
Complement regulators as novel targets for anti-cancer therapy: A comprehensive review., PMID:39826189
Single-Cell Transcriptomics Identifies Selective Lineage-Specific Regulation of Genes in Aortic Smooth Muscle Cells in Mice., PMID:39744838
Identification of plasma proteins binding oxidized phospholipids using pull-down proteomics and OxLDL masking assay., PMID:39566852
SARS-CoV-2 hijacks host CD55, CD59 and factor H to impair antibody-dependent complement-mediated lysis., PMID:39435487
Shiga toxin-producing Escherichia coli infection as a precipitating factor for atypical hemolytic-uremic syndrome., PMID:39347991
The primary systemic vasculitis associated optic neuritis: a retrospective analysis in a single center over 10 years., PMID:39312014
Glomerular injury induced by vinyl carbamate in A/J inbred mice: a novel model of membranoproliferative glomerulonephritis., PMID:39309006
Factor H-related protein 1 in systemic lupus erythematosus., PMID:39136026
Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodies., PMID:39104533
Anti-C5 monoclonal antibody treatment showing pathological resolution of complement-mediated atypical hemolytic uremic syndrome: a case report., PMID:39009967
[Clinical characteristics analysis of 4 cases with acute flaccid myelitis in children]., PMID:38955687
Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators., PMID:38817607
A machine learning-based diagnosis modeling of IgG4 Hashimoto's thyroiditis., PMID:38809347
Genetics in neovascular age-related macular degeneration susceptibility and treatment response to anti-VEGF intravitreal injection: A case series study., PMID:38757252
An unusual case of adult-onset still's disease complicated with anti-complement factor H antibodies associated atypical haemolytic uraemic syndrome., PMID:38745129
Adolescence-onset atypical hemolytic uremic syndrome: is it different from infant-onset?, PMID:38704765
Higher Adalimumab Concentration Is Associated With Complete Fistula Healing in Patients With Perianal Fistulizing Crohn's Disease., PMID:38692557
Managing anti-factor H antibody-associated hemolytic uremic syndrome: time for consensus., PMID:38634874
Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange?, PMID:38632123
Characterization of patients with aHUS and associated triggers or clinical conditions: A Global aHUS Registry analysis., PMID:38604995
Promotion of an Antitumor Immune Program by a Tumor-specific, Complement-activating Antibody., PMID:38558134
Bilateral Retinal Venous Occlusion in Atypical Hemolytic-Uremic Syndrome Due to Complement Factor H Mutation., PMID:38536978
Case report: A family of atypical hemolytic uremic syndrome involving a CFH::CFHR1 fusion gene and CFHR3-1-4-2 gene duplication., PMID:38524137
[Challenges and strategies in the treatment of neovascular age-related macular degeneration]., PMID:38462368
Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways., PMID:38401844
Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy., PMID:38233673
[Comparative characteristics of the complement system in patients with C3-glomerulopathy and atypical hemolytic uremic syndrome of chronic course who suffered an acute episode of thrombotic microangiopathy]., PMID:38158966
Thrombotic Microangiopathy After Hematopoietic Stem Cell and Solid Organ Transplantation: A Review for Intensive Care Physicians., PMID:37990516
Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study., PMID:37984551
Modeling complement activation on human glomerular microvascular endothelial cells., PMID:37954621
Complement factor H Y402H polymorphism results in diminishing CD4+ T cells and increasing C-reactive protein in plasma., PMID:37940659
Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis., PMID:37923132
Eculizumab Versus Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome: A Systematic Review., PMID:37905269
Evaluation of the significance of complement-related genes mutations in atypical postinfectious glomerulonephritis: a pilot study., PMID:37845399
Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?, PMID:37833944
Case report: Autoimmune hemolytic anemia caused by warm and cold autoantibodies with complement activation-etiological and therapeutic issues., PMID:37794962
Atypical hemolytic uremic syndrome: genetically-based insights into pathogenesis through an analysis of the complement regulator CD46., PMID:39949759
Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP., PMID:37762692
Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative GN., PMID:37615951
For research use only. Not for human or drug use.
